Document Detail

Effects of riboflavin and folic acid supplementation on plasma homocysteine levels in healthy subjects.
MedLine Citation:
PMID:  16479177     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Observational studies have shown an inverse relationship between vitamin B2 status and total homocysteine levels, a risk factor for cardiovascular disease. We hypothesize that intervention with riboflavin will lower total homocysteine levels. The total homocysteine lowering by the three genotypes (CC, CT, TT) of methylenetetrahydrofolate reductase polymorphism (677C-->T) was also studied. METHODS: The decrease in total homocysteine levels after supplementation with riboflavin (10 mg/d) or folic acid (1 mg/d) for 3 weeks was compared in two groups of healthy subjects (17 per group, matched by age and gender) (Phase 1). Then, both groups received supplementation with folic acid and riboflavin for an additional 3 weeks (Phase 2). RESULTS: During Phase 1, total homocysteine levels were lowered by 2% or 4% after supplementation with riboflavin or folic [corrected] acid, respectively, although neither decrease was statistically significant (P=0.50 and 0.19). Compared to subjects of CC genotype, total homocysteine lowering in subjects of CT genotype was approaching significance (P=0.059) for the folic acid group, but not for the riboflavin group. After Phase 2, total homocysteine levels were not lowered significantly in either the folic acid (1%) or the riboflavin (2%) group. However, in the folic acid-riboflavin combined group, total homocysteine lowering in subjects of TT type was larger when compared to subjects of CC and CT types (P=0.007). CONCLUSIONS: Riboflavin supplementation did not lower total homocysteine levels in healthy subjects with CC type of C677T polymorphism. However, supplementation with folic acid or with both folic acid and riboflavin may be important for CT and TT subjects in optimizing their homocysteine metabolism. These findings are relevant in characterizing the factors controlling the high total homocysteine levels for subjects of CT and TT genotypes.
Cherng Zee Chuang; Adrienne Boyles; Barbara Legardeur; Joseph Su; Shanker Japa; Alfredo Lopez-S
Related Documents :
16953277 - Folic acid administration and antibodies against homocysteinylated proteins in subjects...
12928887 - Synergistic effects of pyrantel and the febantel metabolite fenbendazole on adult toxoc...
17536697 - Hagfish in the new zealand fjords are supported by chemoautotrophy of forest carbon.
17264397 - Mandatory fortification with folic acid in the united states is not associated with cha...
23663357 - The incidence and magnitude of fibrinolytic activation in trauma patients: a reply to a...
7625847 - Arachidonic acid metabolism by human cytochrome p450s 2c8, 2c9, 2e1, and 1a2: regiosele...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of the medical sciences     Volume:  331     ISSN:  0002-9629     ISO Abbreviation:  Am. J. Med. Sci.     Publication Date:  2006 Feb 
Date Detail:
Created Date:  2006-02-15     Completed Date:  2006-03-16     Revised Date:  2006-06-15    
Medline Journal Info:
Nlm Unique ID:  0370506     Medline TA:  Am J Med Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  65-71     Citation Subset:  AIM; IM    
Department of Medicine, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Chromatography, High Pressure Liquid
Dietary Supplements*
Folic Acid / administration & dosage,  pharmacology*
Homocysteine / blood*
Methylenetetrahydrofolate Reductase (NADPH2) / genetics
Polymorphism, Genetic
Riboflavin / administration & dosage,  pharmacology*
Reg. No./Substance:
454-28-4/Homocysteine; 59-30-3/Folic Acid; 83-88-5/Riboflavin; EC Reductase (NADPH2)
Erratum In:
Am J Med Sci. 2006 May;331(5):269

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  AKT pathway is activated by 1, 25-dihydroxyvitamin D3 and participates in its anti-apoptotic effect ...
Next Document:  Relationships between heart rate variability and urinary albumin excretion in patients with type 2 d...